Meat Intake Linked with Stomach Cancer(4/18/2006) A large European study has determined that a high intake of red or processed meats is associated with an increased risk of developing noncardia gastric cancer.
Long-Term Low-Dose Aspirin Does Not Prevent Cancer(7/6/2005) Researchers affiliated with the Women’s Health Study have reported that long-term low-dose aspirin use does not lower the risk of breast, colorectal, or other cancers.
Antioxidant Vitamins May not Prevent GI Cancers(10/8/2004) A Cochrane report has concluded that researchers were unable to find evidence that supplementation with antioxidants prevents gastrointestinal cancers and in fact actually appears to increase overall mortality. The details of this review and meta-analysis appeared in the October 2, 2004 issue of the Lancet.
Eradication of Helicobacter pylori (H. pylori) May Not Affect Precancerous Gastric Lesions(1/22/2004) Researchers from China have reported that antibiotic eradication of H. pylori prevents gastric cancer in persons without pre-malignant gastric lesions but has no apparent impact on those with established pre-malignant lesions. The details of this report were published in the January 14, 2004 issue of the
Journal of the American Medical Society.
Removal of More Lymph Nodes May Improve Survival in Gastric and Pancreatic Cancers(8/4/2008) Researchers affiliated with the Cancer Programs, American College of Surgeons, recommend that at least 15 lymph nodes be removed and examined in patients with early gastric or pancreatic cancers. The results of this study were published in the July 2008 issue of the Archives of Surgery.
Chlorhexidine or Oral Cooling Decrease Chemotherapy-induced Mucositis(3/31/2008) Researchers from Denmark have reported that chlorhexidine mouth washes or oral cooling decreases the incidence and severity of oral mucositis associated with 5 FU and leucovorin-based chemotherapy for gastrointestinal cancer. The details of this randomized study appeared in an early online publication in Cancer on February 15, 2008.
Combination of Chemotherapy and Immunotherapy Shows Promise for Gastric Cancer(3/28/2008) Researchers from South Korea have reported that a combination of chemotherapy and immunotherapy may improve overall survival of patients with locally advanced gastric cancer undergoing curative surgery. The details of this randomized Phase III trial were published in the March, 2008 issue of the Annals of Oncology.
S-1 Plus Platinol® Effective for Advanced Gastric Cancer(2/22/2008) Researchers from Japan have reported that the combination of S-1 plus Platinol® (cisplatin) is superior to S-1 alone for the treatment of advanced gastric cancer. The details of this study appeared in an early online publication on February 18, 2008, in Lancet Oncology.
No Advantage to the Addition of Platinol® to Camptosar®/5-FU for Advanced Gastric Cancer(4/3/2008) Researchers from Korea have reported that the addition of Platinol® (cisplatin) to Camptosar® (irinotecan), 5-FU, and leucovorin for the treatment of patients with gastric cancer offers no survival benefit. These findings were published in the April 2008 issue of the Annals of Oncology.
Chlorhexidine or Oral Cooling Decrease Chemotherapy-induced Mucositis(3/31/2008) Researchers from Denmark have reported that chlorhexidine mouth washes or oral cooling decreases the incidence and severity of oral mucositis associated with 5 FU and leucovorin-based chemotherapy for gastrointestinal cancer. The details of this randomized study appeared in an early online publication in Cancer on February 15, 2008.
S-1 Plus Platinol® Effective for Advanced Gastric Cancer(2/22/2008) Researchers from Japan have reported that the combination of S-1 plus Platinol® (cisplatin) is superior to S-1 alone for the treatment of advanced gastric cancer. The details of this study appeared in an early online publication on February 18, 2008, in Lancet Oncology.
Sutent® Effective for Gleevec®-Resistant Gastrointestinal Stromal Tumor(10/16/2006) An international randomized trail has determined that Sutent (sunitinib malate, SU11248) improves disease control and survival in patients with Gleevec® (imatinib mesylate) resistant gastrointestinal stromal tumor (GIST).
Xeloda® and Eloxatin® May Replace 5-FU and Platinol® for Treatment of Esophagogastric Cancer(7/3/2006) Researchers affiliated with the REAL 2 Trial have concluded that Xeloda (capecitabine) can replace 5-FU (5-fluorouracil) and Eloxatin (oxaliplatin) can replace Platinol® (cisplatin) for the treatment of cancers of the esophagus, esophageal junction or stomach. The details of this randomized phase III study were presented at the June 2006 meeting of the American Society of Clinical Oncology in Atlanta.
Large Clinical Trial Confirms Activity of Gleevec® For Treatment of Patients With Gastrointestinal Stromal Tumors(8/16/2002) Gastrointestinal stromal tumors are relatively rare cancers that originate in mesenchymal tissue. This tumor is associated with the expression of the KIT proto-oncogene and the production of tyrosine kinase, which leads to uncontrolled growth and suppression of apoptosis. Until the development of Gleevec®, there was no effective systemic treatment for this tumor and the prognosis for patients with recurrent local disease or metastatic disease was poor. Early clinical trials in a limited number of patients showed remarkable responses of gastrointestinal stromal tumors to Gleevec®. Gleevec® is a tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia. The results of a multicenter trial were reported in the August 15, 2002 issue of
The New England Journal of Medicine.
Patient Home
